Accéder au contenu
Merck
Toutes les photos(2)

Key Documents

View All Documentation

S3378

Sigma-Aldrich

Spironolactone

97.0-103.0% (HPLC), powder, aldosterone receptor antagonist

Synonyme(s) :

4-Pregnen-21-oic acid-17α-ol-3-one-7α-thiol γ-lactone 7-acetate, 7α-(Acetylthio)-17α-hydroxy-3-oxopregn-4-ene-21-carboxylic acid γ-lactone

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(2)

About This Item

Formule empirique (notation de Hill):
C24H32O4S
Numéro CAS:
52-01-7
Poids moléculaire :
416.57
Numéro CE :
200-133-6
Numéro MDL:
MFCD00082250
Code UNSPSC :
51111800
ID de substance PubChem :
24277736
Nomenclature NACRES :
NA.77

product name

Spironolactone, 97.0-103.0%

Niveau de qualité

200

Pureté

97.0-103.0%

Pf

207-208 °C (lit.)

Solubilité

chloroform: complete 50 mg/ml, clear, faintly yellow

Chaîne SMILES 

CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]45CCC(=O)O5)[C@H]13

InChI

1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1

Clé InChI

LXMSZDCAJNLERA-ZHYRCANASA-N

Informations sur le gène

human ... HSD17B1(3292) , NR3C2(4306)
rat ... Ar(24208)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Application

Spironolactone was added to rat diet to study the effect of long-term spironolactone use on renal function.

Actions biochimiques/physiologiques

Spironolactone reduces aldosterone-induced potassium/magnesium loss and myocardial fibrosis. It reduces hypertension, improves the endothelial function and reduces the overall morbidity and mortality in patients with chronic heart failure. Spironolactone improves nitric oxide bioactivity and vascular endothelial vasodilator dysfunction.
Spironolactone is a competitive aldosterone receptor antagonist. Used as potassium sparing diuretic.

Caractéristiques et avantages

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Notes préparatoires

Spironolactone yields clear, faint yellow solution in chloroform at 50 mg/ml.

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Danger

Mentions de danger

H351,H360FD,H373

Classification des risques

Carc. 2 - Repr. 1B - STOT RE 2

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

Eyeshields, Gloves, type P2 (EN 143) respirator cartridges

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 5

1 of 5

Eplerenone European Pharmacopoeia (EP) Reference Standard, European Pharmacopoeia (EP) Reference Standard

Y0001704

Eplerenone

Canrenone European Pharmacopoeia (EP) Reference Standard

C0410000

Canrenone

Canrenoic acid potassium salt powder

Sigma-Aldrich

C7287

Canrenoic acid potassium salt

Pravastatin, Sodium Salt A water-soluble, competitive 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor that potently blocks in vivo cholesterol synthesis (Ki = ~1 nM).

Sigma-Aldrich

524403

Pravastatin, Sodium Salt

vibrant-m

D0600000

Deslanoside

Neil Chapman et al.
Hypertension (Dallas, Tex. : 1979), 49(4), 839-845 (2007-02-21)
Spironolactone is recommended as fourth-line therapy for essential hypertension despite few supporting data for this indication. We evaluated the effect among 1411 participants in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm who received spironolactone mainly as a fourth-line antihypertensive
A Sato et al.
Hypertension research : official journal of the Japanese Society of Hypertension, 22(1), 17-22 (1999-04-30)
There is increasing evidence for important cardiovascular effects of aldosterone via classical mineralocorticoid receptors in the heart. Administration of aldosterone with excess salt produces both cardiac hypertrophy and interstitial cardiac fibrosis in rats, and concomitant administration of potassium canrenoate at
P Moghetti et al.
The Journal of clinical endocrinology and metabolism, 84(4), 1250-1254 (1999-04-13)
GnRH agonists (GnRHa) have recently been proposed for the treatment of hirsutism in women with the polycystic ovary syndrome (PCOS). As most of these subjects have increased androgen secretion from both ovaries and adrenal glands, the association of GnRHa with
Femke Waanders et al.
American journal of physiology. Renal physiology, 296(5), F1072-F1079 (2009-02-27)
Chronic transplant dysfunction (CTD) is the leading cause of long-term renal allograft loss and is characterized by specific histological lesions including transplant vasculopathy, interstitial fibrosis, and focal glomerulosclerosis. Increasing evidence indicates that aldosterone is a direct mediator of renal damage
Donna A Volpe et al.
The AAPS journal, 16(1), 172-180 (2013-12-18)
Drug interactions due to efflux transporters may result in one drug increasing or decreasing the systemic exposure of a second drug. The potential for in vivo drug interactions is estimated through in vitro cell assays. Variability in in vitro parameter
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique